I am an investor

Read more

I want to know more about Cantargia's research

Read more

I want to know more about Cantargia as a company

Read more

Presentation at ASCO 2019, follow up articles and interviews

Read more

Cantargia interview at EFN after ASCO

To the interview (in Swedish)

Cantargia partners up with pioneer within biotech industry

Read more

A brief introduction to Cantargia

To the interview

Two Nobel Prizes with utmost significance for Cantargia’s research

Read more
Press releases

2019-10-10 (R) Cantargia reports filing of opposition against Cantargia patent in Europe

2019-09-04 (R) Cantargia submits request for pre-IND meeting on CAN04 with US FDA

2019-08-23 (R) Cantargia announce positive preclinical data on CAN04 in bladder cancer

(R) = Regulatory press releases

”During 2018, we concluded the first very important part of the clinical development of CAN04 and presented patient data that strengthens our hopes that CAN04 can become an important part of tomorrow’s cancer treatment”

Göran Forsberg
CEO Cantargia
Analysis

2019-11-04 Redeye analysis of Cantargia (in Swedish)

2019-08-23 Nordea analysis of Cantargia

2019-06-28, Aktiespararna analysis of Cantargia (In Swedish)

2019-06-20, Økonomisk Ugebrev analysis of Cantargia (In Danish)

Presentations

2019-10-07, Presentation, Oncology Forum 2019, Stockholm

2019-09-05 Presentation, Cantargia presentation 19TH ANNUAL BIOTECH IN EUROPE FORUM 26 Sept, 2019, Basel, Switzerland

2019-09-05 Presentation, Pareto Healthcare Securities Conference 2019, Stockholm

2019-08-29, Video, LSX Nordic Congress 2019, Stockholm

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2019 · Cantargia AB